Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

In this phase 1 trial, treatment of patients with solid tumors using the focal adhesion kinase (FAK) inhibitor defactinib the RAF–MEK clamp avutometinib was safe and showed encouraging clinical responses, especially in patients with low-grade serous ovarian cancer.